Jiangsu Hechen Pharmaceutical Co., Ltd.

Primary objective: To evaluate the effectiveness of arformoterol tartrate nebulized inhalation solution in the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Secondary objective: To observe the safety of arformoterol tartrate nebulized inhalation solution in the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD).

Main study objectives To study the pharmacokinetics of a single oral dose of the test preparation lipoic acid tablets (specification: 0.6g, licensee: Jiangsu Hechen Pharmaceutical Co., Ltd.) and the reference preparation lipoic acid tablets (Thioctacid®, specification: 0.6g, licensee: MEDA Pharma GmbH & Co. KG/Viatris Healthcare GmbH) in healthy adult subjects under fasting conditions, and to evaluate the bioequivalence of the two preparations when taken orally on an empty stomach. Secondary study objectives To evaluate the safety of a single oral dose of the test preparation lipoic acid tablets and the reference preparation lipoic acid tablets (Thioctacid®) in healthy Chinese subjects under fasting conditions.

Main study objectives To study the pharmacokinetic (PK) characteristics of carbidopa and levodopa in healthy Chinese subjects after a single oral administration of carbidopa 50 mg, levodopa 200 mg, provided by Jiangsu Hechen Pharmaceutical Co., Ltd. and reference preparation (carbidopa 50 mg, levodopa 200 mg, Xining®; licensee: MSD Sharp & Dohme GmbH) in fasting and fed states, and to evaluate the bioequivalence of the two preparations in fasting and fed states. Secondary study objectives To evaluate the safety of the test preparation carbidopa 50 mg and reference preparation carbidopa 50 mg after a single oral administration in fasting and fed states in healthy Chinese subjects.